IDEXX Surges 4.14% on $510M Volume Ranking 214th as Analysts Hike 2025 Forecasts and Price Target 24%

On August 7, 2025, IDEXX Laboratories (IDXX) rose 4.14% to close at $610.50, with a trading volume of $510 million. The stock ranked 214th in market activity. Recent analyst forecasts highlight improved earnings estimates, with revenue projections for 2025 lifted to $4.23 billion, reflecting a 4.7% year-over-year growth. Earnings per share (EPS) are expected to rise 2.2% to $12.59, driven by stronger-than-expected Q2 results. Analysts also raised the consensus price target by 24% to $674, signaling increased confidence in the company’s intrinsic value.

Following Q2 earnings, IDEXX reported revenue of $1.1 billion, exceeding estimates by 4.0%, and EPS of $3.63, outpacing forecasts by 10%. The company raised full-year guidance to $12.40–$12.76 per share and 2025 sales to $4.21–$4.28 billion. Analysts revised 2025 revenue forecasts upward, aligning with the company’s growth trajectory. While IDEXX’s projected revenue growth matches the broader industry’s 8.2% annualized rate, its earnings upgrades suggest stronger near-term performance compared to peers.

A backtest of a strategy buying the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 yielded a 166.71% return, outperforming the benchmark by 137.53%. This underscores liquidity concentration in high-volume stocks as a key driver of short-term gains, particularly in volatile markets.